<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:53:09Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7969746" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7969746</identifier>
        <datestamp>2021-04-12</datestamp>
        <setSpec>bloodcancer</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="letter">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Blood Cancer J</journal-id>
              <journal-id journal-id-type="iso-abbrev">Blood Cancer J</journal-id>
              <journal-title-group>
                <journal-title>Blood Cancer Journal</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-5385</issn>
              <publisher>
                <publisher-name>Nature Publishing Group UK</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7969746</article-id>
              <article-id pub-id-type="pmcid">PMC7969746</article-id>
              <article-id pub-id-type="pmc-uid">7969746</article-id>
              <article-id pub-id-type="pmid">33731681</article-id>
              <article-id pub-id-type="publisher-id">453</article-id>
              <article-id pub-id-type="doi">10.1038/s41408-021-00453-z</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Correspondence</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II study</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8433-3360</contrib-id>
                  <name>
                    <surname>Reville</surname>
                    <given-names>Patrick K.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1908-3307</contrib-id>
                  <name>
                    <surname>Kantarjian</surname>
                    <given-names>Hagop M.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ravandi</surname>
                    <given-names>Farhad</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jabbour</surname>
                    <given-names>Elias</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9003-0390</contrib-id>
                  <name>
                    <surname>DiNardo</surname>
                    <given-names>Courtney D.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Daver</surname>
                    <given-names>Naval</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pemmaraju</surname>
                    <given-names>Naveen</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ohanian</surname>
                    <given-names>Maro</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Alvarado</surname>
                    <given-names>Yesid</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Xiao</surname>
                    <given-names>Lianchun</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Alatrash</surname>
                    <given-names>Gheath</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Loghavi</surname>
                    <given-names>Sanam</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4166-5717</contrib-id>
                  <name>
                    <surname>Rausch</surname>
                    <given-names>Caitlin R.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7679-6453</contrib-id>
                  <name>
                    <surname>Borthakur</surname>
                    <given-names>Gautam</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9347-2212</contrib-id>
                  <name>
                    <surname>Konopleva</surname>
                    <given-names>Marina</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8636-1071</contrib-id>
                  <name>
                    <surname>Cortes</surname>
                    <given-names>Jorge</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9892-9832</contrib-id>
                  <name>
                    <surname>Kadia</surname>
                    <given-names>Tapan M.</given-names>
                  </name>
                  <address>
                    <email>tkadia@mdanderson.org</email>
                  </address>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Division of Cancer Medicine, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>1400 Holcombe Boulevard, Houston, TX USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Leukemia, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>1400 Holcombe Boulevard, Houston, TX USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Biostatistics, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>1400 Holcombe Boulevard, Houston, TX USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Stem Cell Transplantation &amp; Cellular Therapy, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>1400 Holcombe Boulevard, Houston, TX USA </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Department of Hematopathology, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>1400 Holcombe Boulevard, Houston, TX USA </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>Division of Pharmacy, </institution><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>1400 Holcombe Boulevard, Houston, TX USA </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.410427.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2284 9329</institution-id><institution>Georgia Cancer Center, </institution><institution>Augusta University, </institution></institution-wrap>1411 Laney Walker Blvd, Augusta, Georgia </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>17</day>
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>17</day>
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>3</month>
                <year>2021</year>
              </pub-date>
              <volume>11</volume>
              <issue>3</issue>
              <elocation-id>60</elocation-id>
              <history>
                <date date-type="received">
                  <day>22</day>
                  <month>9</month>
                  <year>2020</year>
                </date>
                <date date-type="rev-recd">
                  <day>6</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>10</day>
                  <month>2</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2021</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <kwd-group kwd-group-type="npg-subject">
                <title>Subject terms</title>
                <kwd>Immunotherapy</kwd>
                <kwd>Acute myeloid leukaemia</kwd>
                <kwd>Phase II trials</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000002</institution-id>
                      <institution>U.S. Department of Health &amp; Human Services | National Institutes of Health (NIH)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>T32CA009666</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Reville</surname>
                      <given-names>Patrick K.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000054</institution-id>
                      <institution>U.S. Department of Health &amp; Human Services | NIH | National Cancer Institute (NCI)</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>CA100632</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Kantarjian</surname>
                      <given-names>Hagop M.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">https://doi.org/10.13039/100007313</institution-id>
                      <institution>UT | University of Texas MD Anderson Cancer Center (MD Anderson)</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p id="Par1">Dear Editor,</p>
            <p id="Par2">Patients with high-risk AML ineligible for allogeneic hematopoietic stem cell transplantation (allo-SCT) have poor outcomes and low likelihood of cure<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Maintenance cytotoxic chemotherapy in AML has consistently failed to show a benefit<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Recent data suggest that there may be a role for hypomethylating agents (HMAs) as maintenance therapy in older individuals with AML<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>.</p>
            <p id="Par3">Therapies that engage the immune system have the ability to induce durable remissions. A major mechanism in the maintenance of remission and cure of AML with allo-SCT is graft-versus-leukemia effect<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. Given the need for novel therapeutic approaches for high-risk AML patients, we designed a pilot phase II clinical trial studying the efficacy and safety of the immune checkpoint inhibitor nivolumab as maintenance therapy in AML. Here we report the results of the first single arm, open-label trial of maintenance nivolumab in patients with high-risk AML in remission not being considered for allo-SCT.</p>
            <p id="Par4">Eligible patients had adequate organ function, an ECOG performance status of ≤2, and AML in remission (defined as CR, CR with incomplete hematologic recovery [CRi], or partial remission [PR]). Patients were defined as having high-risk disease by any of the following: in 1st CR with secondary AML; high-risk cytogenetics at diagnosis; fms-related tyrosine kinase 3 internal tandem duplication mutated at diagnosis; the presence of measurable residual disease assessed by flow cytometry at time of enrollment; or 2nd CR or greater regardless of disease characteristics at the time of initial diagnosis. Patients must have received induction and at least one cycle of consolidation chemotherapy and should have achieved a CR within 12 months of protocol enrollment.</p>
            <p id="Par5">Patients must have not been on steroids (&gt;10 mg prednisone/day or equivalent) or other immunosuppressive medication. Patients with a history of autoimmune disease, positive for hepatitis B surface antigen expression, active hepatitis C infection, or known HIV infection were excluded. The study was approved by the University of Texas MD Anderson Cancer Center Institutional Review Board. All patients signed a written informed consent and the trial was conducted in accordance with the Declaration of Helsinki.</p>
            <p id="Par6">Patients received nivolumab at a dose of 3 mg/kg intravenously every 2 weeks. Cycles repeated every 28 days in the absence of disease progression or unacceptable toxicity. After cycle 6, patients received nivolumab every 4 weeks. After cycle 12, patients received nivolumab every 3 months until disease relapse. All toxicity was graded by Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</p>
            <p id="Par7">The primary outcome was recurrence-free survival (RFS) rate at six months. Secondary outcomes were to evaluate measurable residual disease (MRD) by flow cytometry as a predictor of response and MRD dynamics with nivolumab therapy; to evaluate time to relapse and overall survival; to evaluate the toxicity profile of nivolumab among patients with AML.</p>
            <p id="Par8">MRD was assessed prior to disease enrollment and as a part of standard practice with each bone marrow biopsy. Multicolor flow cytometry was utilized to assess MRD status to achieve a sensitivity of 0.01%<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>.</p>
            <p id="Par9">For the primary efficacy endpoint, the study was continuously monitoring RFS for futility and the study was to be stopped early if at any time the data suggest that there is less than 25% probability that the median RFS was longer than that in the historical data, 8 months that corresponds to an RFS rate at 6 months of 59.5%. The study was continuously monitored for toxicity and the trial was to be stopped if at any point there was more than an 88% probability that the toxicity rate (defined as any treatment-related clinically significant grade 3 or worse non-hematologic event) of the maintenance therapy with nivolumab is greater than 30%.</p>
            <p id="Par10">The Kaplan–Meier method was used to estimate the median recurrence-free and overall survival probabilities. Statistical analyses were carried out using R. This study is registered with ClinicalTrials.gov, NCT02532231.</p>
            <p id="Par11">From November 11, 2015 through August 15, 2018, 15 patients were enrolled. The median age was 56 (range: 31–71). Based on the European Leukemia Network (ELN) classification, 6 (40%) were adverse, 4 (27%) were intermediate, and 5 (33%) were favorable risk at diagnosis. Nine of the fifteen patients (60%) had detectable MRD at the time of enrollment. At enrollment, 7 patients (47%) were in CR, 7 (47%) patients were CRi, and one patient was in PR. Eight patients were in the first remission and seven were in second remission or greater (Supplemental Table <xref rid="MOESM1" ref-type="media">1</xref>).</p>
            <p id="Par12">Patients received a median of 6 (range: 1–23) cycles of therapy. With a median follow up of 30.4 months, the estimated 6-month RFS is 57.1% (95% CI: 36.3–89.9%) and median RFS was 8.48 months (95% CI: 2.14–NE) (Fig. <xref rid="Fig1" ref-type="fig">1A</xref>). Two patients proceeded to allo-SCT. One patient, received a peripheral blood stem cell allo-SCT 3 months after last dose of nivolumab, developed grade 4 gastrointestinal graft-versus-host disease and died. The other patient did not develop GvHD. The median overall survival has not yet been reached (95% CI: 10.3 months–NE) (Fig. <xref rid="Fig1" ref-type="fig">1B</xref>). Cause of death and post-protocol therapies are outlined in Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><title>Survival and MRD Dynamics.</title><p><bold>A</bold> Kaplan–Meier curve showing recurrence-free survival of the fifteen patients treated with maintenance nivolumab. <bold>B</bold> Kaplan–Meier curve showing overall survival of the fifteen patients treated with maintenance nivolumab. <bold>C</bold> Kaplan–Meier curve showing progression-free survival stratified by MRD status at study enrollment. <bold>D</bold> Kaplan–Meier curve overall survival stratified by MRD status at study enrollment. <bold>E</bold> Swimmer plot showing overall survival of nine patients with detectable MRD at enrollment along with one patient with undetectable MRD that relapsed. Black dot represents patient death while black arrow represents ongoing MRD negative CR. <bold>F</bold> MRD dynamics of the remaining seven patient with positive MRD at enrollment that did not clear MRD while on treatment with maintenance nivolumab. <bold>G</bold> MRD dynamics of patient #1 as measured by flow cytometry while on treatment with maintenance nivolumab. <bold>H</bold> MRD dynamics of patient #8 as measured by flow cytometry while on treatment with maintenance nivolumab.</p></caption><graphic xlink:href="41408_2021_453_Fig1_HTML" id="d32e516"/></fig></p>
            <p id="Par13">Six patients were MRD negative at the start of nivolumab maintenance therapy with one experiencing AML recurrence (Fig. <xref rid="Fig1" ref-type="fig">1C/E</xref>). Nine patients were MRD positive at the time of enrollment; median level of MRD was 0.6% (range: 0.07–4.3%). Seven of the nine (78%) patients with detectable MRD at enrollment continued to have detectable MRD with progressive disease, despite nivolumab, until frank disease recurrence (Fig. <xref rid="Fig1" ref-type="fig">1G</xref>).</p>
            <p id="Par14">Two of nine patients cleared MRD while on treatment with nivolumab. Patient 1 had 0.6% MRD at enrollment and by 7.5 months of treatment with nivolumab had eradication of detectable MRD with no further recurrence (Fig. <xref rid="Fig1" ref-type="fig">1F</xref>). This patient had favorable risk disease, with diploid cytogenetics and mutations in <italic>DNMT3A</italic>, <italic>IDH2</italic>, and <italic>NPM1</italic> at diagnosis, and was in MRD positive CR1 at enrollment following induction with cladribine, idarubicin, and cytarabine.</p>
            <p id="Par15">Patient 8 had 0.07% MRD at enrollment and after one month of nivolumab maintenance, no longer had detectable MRD. This patient remains in an MRD negative CR (Fig. <xref rid="Fig1" ref-type="fig">1H</xref>). At diagnosis, this patient had intermediate-risk disease, with diploid cytogenetics and a <italic>DNMT3A</italic> mutation, and was in CR2 after induction and re-induction with 7+3.</p>
            <p id="Par16">Adverse events independent of causality are summarized in Table <xref rid="Tab1" ref-type="table">1</xref>. There were 11 grade 3/4 non-immune-related adverse events experienced in 5 patients. 6 patients developed immune-related adverse events (irAE). One patient had grade 2 thyroiditis that required treatment with corticosteroids and thyroid hormone replacement; one patient developed grade 4 alanine aminotransferase elevation and grade 3 aspartate aminotransferase elevation which responded to dose interruption alone; two patients developed grade 3 pneumonitis treated with corticosteroids and dose interruption. These 4 patients resumed treatment with nivolumab after interruption and improvement in irAE. One patient developed warm autoimmune hemolytic anemia as an irAE during cycle 1 and came off study. One other patient discontinued therapy due to irAE, this patient had persistent eosinophilia (grade 1) and allergic rhinitis (grade 2) while on maintenance nivolumab which was discontinued after 13 cycles while in an MRD negative CR and has remained alive and without recurrence since discontinuation. After discontinuation, these symptoms improved.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Adverse events.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="4">Grade</th></tr><tr><th>Adverse event, <italic>n</italic> (%)</th><th>G1</th><th>G2</th><th>G3</th><th>G4</th></tr></thead><tbody><tr><td colspan="5"><italic>Blood and lymphatic system disorders</italic></td></tr><tr><td>Eosinophilia</td><td>1 (7%)</td><td/><td/><td/></tr><tr><td>Febrile neutropenia</td><td/><td/><td>1 (7%)</td><td/></tr><tr><td>Hemolysis</td><td/><td/><td/><td>1 (7%)</td></tr><tr><td colspan="5"><italic>Cardiac disorders</italic></td></tr><tr><td>Chest Pain</td><td>2 (13%)</td><td/><td/><td/></tr><tr><td>Hypotension</td><td/><td/><td>1 (7%)</td><td/></tr><tr><td colspan="5"><italic>Endocrine disorders</italic></td></tr><tr><td>Hypothyroidism</td><td/><td>1 (7%)</td><td/><td/></tr><tr><td colspan="5"><italic>Eye disorders</italic></td></tr><tr><td>Photophobia</td><td>1 (7%)</td><td/><td/><td/></tr><tr><td colspan="5"><italic>Gastrointestinal disorders</italic></td></tr><tr><td>Abdominal Pain</td><td/><td/><td>1 (7%)</td><td/></tr><tr><td>Diarrhea</td><td>3 (20%)</td><td>2 (13%)</td><td/><td/></tr><tr><td>Distension/bloating, abdominal</td><td>1 (7%)</td><td/><td/><td/></tr><tr><td>Gastroesophageal reflux disease</td><td/><td>1 (7%)</td><td/><td/></tr><tr><td>Mucositis/stomatitis</td><td>1 (7%)</td><td/><td/><td/></tr><tr><td>Nausea</td><td/><td>1 (7%)</td><td/><td/></tr><tr><td>Sore Throat</td><td/><td>1 (7%)</td><td/><td/></tr><tr><td>Vomiting</td><td/><td/><td>1 (7%)</td><td/></tr><tr><td>Oral Pain</td><td>1 (7%)</td><td/><td/><td/></tr><tr><td colspan="5"><italic>General disorders and administration site conditions</italic></td></tr><tr><td>Edema Limbs</td><td>1 (7%)</td><td/><td/><td/></tr><tr><td>Fatigue</td><td>1 (7%)</td><td>1 (7%)</td><td/><td/></tr><tr><td>Flu like symptoms</td><td>1 (7%)</td><td>1 (7%)</td><td/><td/></tr><tr><td><italic>Infections and infestations</italic></td><td/><td/><td/><td/></tr><tr><td>Upper respiratory infection</td><td/><td>2 (13%)</td><td/><td/></tr><tr><td>Lung Infection</td><td/><td/><td/><td/></tr><tr><td>Sepsis</td><td/><td/><td>1 (7%)</td><td/></tr><tr><td><italic>Investigations</italic></td><td/><td/><td/><td/></tr><tr><td>Alanine aminotransferase increased</td><td/><td>2 (13%)</td><td>1 (7%)</td><td>1 (7%)</td></tr><tr><td>Aspartate aminotransferase increased</td><td/><td/><td>1 (7%)</td><td/></tr><tr><td colspan="5"><italic>Musculoskeletal and connective tissue disorders</italic></td></tr><tr><td>Arthralgia</td><td/><td>1 (7%)</td><td/><td/></tr><tr><td>Back Pain</td><td/><td>1 (7%)</td><td/><td/></tr><tr><td colspan="5"><italic>Nervous system disorders</italic></td></tr><tr><td>Dizziness</td><td>2 (13%)</td><td/><td/><td/></tr><tr><td colspan="5"><italic>Respiratory, thoracic, and mediastinal disorders</italic></td></tr><tr><td>Pneumonitis</td><td/><td/><td>2 (13%)</td><td/></tr><tr><td>Cough</td><td/><td>1 (7%)</td><td/><td/></tr><tr><td>Allergic Rhinitis</td><td/><td>1 (7%)</td><td/><td/></tr><tr><td>Cough</td><td>1 (7%)</td><td/><td/><td/></tr><tr><td>Hemoptysis</td><td/><td>1 (7%)</td><td/><td/></tr><tr><td>Nasal Congestion</td><td>1 (7%)</td><td/><td/><td/></tr><tr><td colspan="5"><italic>Skin and subcutaneous tissue disorders</italic></td></tr><tr><td>Hyperpigmentation</td><td>1 (7%)</td><td/><td/><td/></tr><tr><td>Pruritus/itching</td><td>4 (27%)</td><td>1 (7%)</td><td/><td/></tr><tr><td>Rash</td><td>1 (7%)</td><td/><td/><td/></tr></tbody></table></table-wrap></p>
            <p id="Par17">This study demonstrated the safety and feasibility of maintenance nivolumab for patients with high-risk AML. It showed a modest effect in eradicating MRD and extending remissions as a single-agent. Notably, the two patients who achieved MRD eradication on study had the lowest positive levels in the cohort. In high-risk AML patients, the relapse rate is high, with a very short disease free survival<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. The most effective post-remission therapy in high-risk AML continues to be allo-SCT which is not universally available<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref></sup>. Recently, maintenance oral azacitidine was shown to improve both relapse-free and overall survival<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. The combination of HMA and nivolumab may have additive effects in the maintenance setting. For instance, the combination of nivolumab and azacitidine in the relapsed/refractory AML setting produced a response rate of 33%<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. However, in an early analysis of durvalumab in combination with azacitadine for frontline treatment did not appear to improve outcomes for older patients with AML<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>.</p>
            <p id="Par18">Grade 3/4 irAEs were observed in 27% of the patients. The irAEs frequently occurred within 8 weeks after nivolumab initiation with all grade 3–4 irAEs were treated with systemic steroids and/or dose interruptions resulting in toxicity resolution and successful re-challenge with nivolumab in all but 1 patient.</p>
            <p id="Par19">In conclusion, nivolumab maintenance produced recurrence-free survival duration similar to historical observation, but encouraging overall survival in high-risk AML patients not being considered for allo-SCT. Multiple clinical trials are ongoing including a randomized trial of PD-1 inhibitor for eradication of MRD in high-risk AML in remission (NCT02275533). While not supporting the use of single-agent nivolumab in this setting, this data provides background and feasibility for incorporating immune checkpoint blockade in combination trials for maintenance therapy in high-risk AML patients.</p>
            <sec sec-type="supplementary-material">
              <title>Supplementary information</title>
              <sec id="Sec1">
                <supplementary-material content-type="local-data" id="MOESM1">
                  <media xlink:href="41408_2021_453_MOESM1_ESM.docx">
                    <caption>
                      <p>Supplement</p>
                    </caption>
                  </media>
                </supplementary-material>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <sec>
              <title>Supplementary information</title>
              <p>The online version contains supplementary material available at 10.1038/s41408-021-00453-z.</p>
            </sec>
            <ack>
              <title>Acknowledgements</title>
              <p>The authors thank the patients and their families who participated in this clinical trial. We also thank the research coordinators, research nurses, advance practice providers, and other staff for their support of this clinical trial. This work was supported by Bristol-Myers Squibb, the MD Anderson Cancer Center Leukemia Support Grant CA016672, the MD Anderson Cancer Center Leukemia SPORE CA100632, and the MD Anderson Moon Shots Program. PKR is supported by a T32 grant from the NIH (T32CA009666). This work was previously presented at EHA 2017 and ASCO 2018.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>H.K., J.C., and T.M.K. conceived, designed, and conducted the study; P.K.R., L.X., and T.M.K. acquired and analyzed the data; P.K.R., H.K., J.C., and T.M.K. interpreted the results; H.K., F.R., E.J., C.D.D., N.D., N.P., M.O., Y.A., G.B., M.K., J.C., and T.M.K. treated patients on study. P.K.R., H.K., F.R., E.J., C.D.D., N.D., N.P., M.O., Y.A., L.X., G.A., S.L., C.R., G.B., M.K., J.C., and T.M.K. critically reviewed or revised the manuscript for intellectual content; and P.K.R. and T.M.K drafted the manuscript with input from the coauthors.</p>
            </notes>
            <notes id="FPar1" notes-type="COI-statement">
              <title>Conflict of interest</title>
              <p id="Par20">HMK: Consulting/honorarium: AbbVie, Actinium (Advisory Board), Agios, Amgen, Immunogen, Pfizer. Research Grants: AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, Pfizer. FR: Research funding and member of advisory boards from BMS. EJ: Research grants and consultancy from Abbvie, Adaptive biotechnology, Amgen, BMS, Genentech, Pfizer, and Takeda. CDD: Research grants (to institution): Abbvie, Agios, Calithera, Celgene, Daiichi-Sankyo. Consultant/Advisory Boards: Abbvie, Agios, Celgene, Daiichi Sankyo, ImmuneOnc, Novartis, Takeda, Notable Labs. ND: Consulting/honorarium: BMS, Novartis, Jazz, Daiichi-Sankyo, Astellas, Abbvie, Genentech, Immunogen, Trillium, Forty-Seven, Gilead, Syndax, Kite, Pfizer. Research grants: BMS, Pfizer, Abbvie, Genentech, Astellas, Daiichi-Sankyo, Immunogen, Novimmune, Trovagene, Amgen, Hanmi, Fate, Forty-Seven. NP: Consulting/honorarium: Celgene; Stemline; Incyte; Novartis; MustangBio; Roche Diagnostics, LFB, Pacylex, AbbVie; Research grants: Stemline; Novartis; AbbVie; Samus; Cellectis; Plexxikon; Daiichi-Sankyo; Affymetrix, SagerStrong Foundation. MK: Consulting/honorarium: AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Amgen, Forty-Seven, Kisoji, Reata Pharmaceutical. Research grants: AbbVie, Genentech, F. Hoffman La-Roche, Stemline Therapeutics, Forty-Seven, Kisoji, Eli Lilly, Cellectis, Calithera, Ablynx, Agios, Ascentage, Astra Zeneca. JC: Consulting/honorarium: Novartis, Pfizer, BiopTah Holdings, Jazz, Takeda. Research grants: BMS, Novartis, Pfizer, Takeda, Jazz, Merus, Astellas, Amphivena, Celgene. TMK: Consulting/honorarium: Novartis, Abbvie, Genentech, Pfizer, JAZZ, Daiichi-Sankyo; Research grants: BMS, Celgene, Pfizer, Incyte, Genentech, Astra Zeneca, Amgen, Abbvie, JAZZ, Cellenkos, Cyclacel. P.K.R., M.O., Y.A., L.X., G.A., S.L., C.R.R., and G.B. all have no conflicts to disclose.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Vasu</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission</article-title>
                  <source>Blood Adv.</source>
                  <year>2018</year>
                  <volume>2</volume>
                  <fpage>1645</fpage>
                  <lpage>50</lpage>
                  <pub-id pub-id-type="doi">10.1182/bloodadvances.2017015222</pub-id>
                  <pub-id pub-id-type="pmid">29991495</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rashidi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Walter</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Tallman</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Appelbaum</surname>
                      <given-names>FR</given-names>
                    </name>
                    <name>
                      <surname>DiPersio</surname>
                      <given-names>JF</given-names>
                    </name>
                  </person-group>
                  <article-title>Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials</article-title>
                  <source>Blood.</source>
                  <year>2016</year>
                  <volume>128</volume>
                  <fpage>763</fpage>
                  <lpage>73</lpage>
                  <pub-id pub-id-type="doi">10.1182/blood-2016-03-674127</pub-id>
                  <pub-id pub-id-type="pmid">27354720</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wei</surname>
                      <given-names>AH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2020</year>
                  <volume>383</volume>
                  <fpage>2526</fpage>
                  <lpage>37</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa2004444</pub-id>
                  <pub-id pub-id-type="pmid">33369355</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Huls</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients</article-title>
                  <source>Blood.</source>
                  <year>2019</year>
                  <volume>133</volume>
                  <fpage>1457</fpage>
                  <lpage>64</lpage>
                  <pub-id pub-id-type="doi">10.1182/blood-2018-10-879866</pub-id>
                  <pub-id pub-id-type="pmid">30630862</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Horowitz</surname>
                      <given-names>MM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Graft-versus-leukemia reactions after bone marrow transplantation</article-title>
                  <source>Blood.</source>
                  <year>1990</year>
                  <volume>75</volume>
                  <fpage>555</fpage>
                  <lpage>62</lpage>
                  <pub-id pub-id-type="doi">10.1182/blood.V75.3.555.555</pub-id>
                  <pub-id pub-id-type="pmid">2297567</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Xu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Jorgensen</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>SA</given-names>
                    </name>
                  </person-group>
                  <article-title>How do we use multicolor flow cytometry to detect minimal residual disease in acute myeloid leukemia?</article-title>
                  <source>Clin Lab Med</source>
                  <year>2017</year>
                  <volume>37</volume>
                  <fpage>787</fpage>
                  <lpage>802</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.cll.2017.07.004</pub-id>
                  <pub-id pub-id-type="pmid">29128069</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Almeida</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Ramos</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Acute myeloid leukemia in the older adults</article-title>
                  <source>Leuk. Res. Rep.</source>
                  <year>2016</year>
                  <volume>6</volume>
                  <fpage>1</fpage>
                  <lpage>7</lpage>
                  <?supplied-pmid 27408788?>
                  <pub-id pub-id-type="pmid">27408788</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rashidi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Weisdorf</surname>
                      <given-names>DJ</given-names>
                    </name>
                    <name>
                      <surname>Bejanyan</surname>
                      <given-names>N</given-names>
                    </name>
                  </person-group>
                  <article-title>Treatment of relapsed/refractory acute myeloid leukaemia in adults</article-title>
                  <source>Br. J. Haematol.</source>
                  <year>2018</year>
                  <volume>181</volume>
                  <fpage>27</fpage>
                  <lpage>37</lpage>
                  <pub-id pub-id-type="doi">10.1111/bjh.15077</pub-id>
                  <pub-id pub-id-type="pmid">29318584</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Koreth</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials</article-title>
                  <source>JAMA.</source>
                  <year>2009</year>
                  <volume>301</volume>
                  <fpage>2349</fpage>
                  <lpage>61</lpage>
                  <pub-id pub-id-type="doi">10.1001/jama.2009.813</pub-id>
                  <pub-id pub-id-type="pmid">19509382</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gragert</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>HLA match likelihoods for hematopoietic stem-cell grafts in the US registry</article-title>
                  <source>N. Engl. J. Med.</source>
                  <year>2014</year>
                  <volume>371</volume>
                  <fpage>339</fpage>
                  <lpage>48</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMsa1311707</pub-id>
                  <pub-id pub-id-type="pmid">25054717</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <mixed-citation publication-type="other">Wei A. H., et al. The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission. 10.1182/blood-2019-132405 (2019).</mixed-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Daver</surname>
                      <given-names>N</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study</article-title>
                  <source>Cancer Discov.</source>
                  <year>2019</year>
                  <volume>9</volume>
                  <fpage>370</fpage>
                  <lpage>83</lpage>
                  <pub-id pub-id-type="doi">10.1158/2159-8290.CD-18-0774</pub-id>
                  <pub-id pub-id-type="pmid">30409776</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zeidan</surname>
                      <given-names>AM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Efficacy and safety of azacitidine (AZA) in combination with the anti-PD-L1 Durvalumab (durva) for the front-line treatment of older patients (pts) with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy (IC) and Pts with higher-risk myelodysplastic syndromes (HR-MDS): results from a large, international, randomized phase 2 study</article-title>
                  <source>Blood.</source>
                  <year>2019</year>
                  <volume>134</volume>
                  <fpage>829</fpage>
                  <pub-id pub-id-type="doi">10.1182/blood-2019-122896</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
